Recce Pharmaceuticals Ltd, a biotechnology company, researches and develops antibiotic drugs in Australia. The company focuses on the development of RECCE 327 that helps to address the problem of antibiotic resistant superbugs. It also develops drugs for the treatment of stomach ulcers and diarrhea. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 2 8075 4585
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.54 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Recce Pharmaceuticals (ASX:RCE) Frequently Asked Questions
What is Recce Pharmaceuticals' stock symbol?
Recce Pharmaceuticals trades on the ASX under the ticker symbol "RCE."
Has Recce Pharmaceuticals been receiving favorable news coverage?
Media stories about RCE stock have trended somewhat positive on Sunday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Recce Pharmaceuticals earned a news impact score of 1.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Recce Pharmaceuticals.
Who are some of Recce Pharmaceuticals' key competitors?
Some companies that are related to Recce Pharmaceuticals include Vita Life Sciences (VLS), Futura Medical (FUM), Patrys (PAB), Cathay International (CTI), Avivagen (VIV), Antisense Therapeutics (ANP), NanoViricides (NNVC), Sareum (SAR), China Pharma (CPHI), N4 Pharma (N4P), Bayer (BAYN), HedgePath Pharmaceuticals (MAYNF), OTSUKA HOLDINGS/ADR (OTSKY), Sanofi (SAN) and SINR PHAR/PAR VTG FPD 0.01 (SPH).
What other stocks do shareholders of Recce Pharmaceuticals own?
Who are Recce Pharmaceuticals' key executives?
Recce Pharmaceuticals' management team includes the folowing people:
- Dr. Graham John Hamilton Melrose BSc(Hons), Ph.D., MBA, FRACI, CChem, FAICD, Exec. Chairman & Chief Research Officer (Age 85)
- Mr. James Hamilton-Bray Graham, Exec. Director and Exec. Director of Marketing & Bus. Devel.
- Ms. Michele Dilizia, Exec. Director and Exec. Director of Regulatory Affairs & Microbiology
- Dr. Justin Ward, Principal Quality Chemist
- Mr. Justin Reynolds, Chief Financial Officer
What is Recce Pharmaceuticals' stock price today?
One share of RCE stock can currently be purchased for approximately A$0.21.
How big of a company is Recce Pharmaceuticals?
What is Recce Pharmaceuticals' official website?
How can I contact Recce Pharmaceuticals?
The company can be reached via phone at 61 2 8075 4585.
MarketBeat Community Rating for Recce Pharmaceuticals (ASX RCE)
MarketBeat's community ratings are surveys of what our community members think about Recce Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
